Evaluation of DW Silicone Hydrogel Lens Compared to DW Silicone Hydrogel Lens
NCT ID: NCT01386008
Last Updated: 2019-09-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
28 participants
INTERVENTIONAL
2011-05-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Dispensing Clinical Trial of a Study Test Silicone Hydrogel Lens Against Control Lens Over 1 Week
NCT02500368
A Contralateral Dispensing Clinical Trial of Study Test Sapphire Lens Against Enfilcon A Silicone Hydrogel Lens
NCT02518490
Clinical Evaluation of Hydrogels vs Silicone Hydrogel Contact Lenses
NCT01966770
Clinical Evaluation of Two Silicone Hydrogel Contact Lenses
NCT05313412
Performance Evaluation of Different Daily Disposable Silicone Hydrogel Contact Lenses
NCT05805059
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
enfilcon A + senofilcon A
Simultaneous wearing of daily wear contact lenses - investigational enfilcon A contact lenses in one eye and comparator senofilcon A worn in the other
senfilcon A contact lens
senofilcon A spherical contact lens worn in a daily wear modality
investigational enfilcon A
investigational enfilcon A, worn daily wear modality
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
senfilcon A contact lens
senofilcon A spherical contact lens worn in a daily wear modality
investigational enfilcon A
investigational enfilcon A, worn daily wear modality
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Not using any ocular medications
3. Have a self-reported full eye examination within 2 years.
4. Have:
* read the Informed Consent
* be given an explanation of the Informed Consent
* indicate understanding of the Informed Consent
* signed the Informed Consent document.
5. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
6. Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses on a daily basis for at least 8 hours per day for at least one month prior to participation in the study.
7. Possess wearable and visually functional eyeglasses.
8. Be in good general health, based on his/her knowledge.
9. Require spectacle lens powers between -1.00 and -6.00 diopters sphere with no more than 0.75 diopter of refractive astigmatism in order to have the best spherical equivalent power of -6.50 or less.
10. Be willing to wear contact lenses in both eyes.
11. Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 (less than or equal to LogMAR 0.10) in each eye.
12. Upon completing the fitting process with the lenses to be worn in the study, have contact lens Snellen VA equal to or better than 20/30 in each eye.
Exclusion Criteria
2. Any active participation in another one-day clinical trial within 7 days prior to this study or another dispensing trial within 30 days prior to this study.
3. Currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the next month.
4. Has a known sensitivity to ingredients used in the over the counter contact lens care approved for use in the study.
5. Previous refractive surgery/anterior segment surgery; or current or previous orthokeratology treatment or irregular cornea.
6. Is aphakic or pseudophakic.
7. Unable to achieve a satisfactory fit with the lens designs used in the study
8. Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermia, keratoconus or type II diabetes.
9. The need for topical ocular medications or any medication which might contradict contact lens wear or which would require the lenses to be removed during the day.
10. The presence of clinically anterior segment infection, inflammations or abnormalities; such as iritis; or any infection of the eye, lids, or associated structures.
11. A history of herpetic keratitis.
12. A known history of corneal hypoesthesia (reduced corneal sensitivity) or active corneal ulcer, corneal infiltrates or fungal infection.
13. A history of papillary conjunctivitis that has interfered with contact lens wear.
14. Slit lamp findings that would contraindicate contact lens wear, including but not limited to:
* Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining \> grade 2
* Pterygium
* Corneal scars within the visual axis
* Corneal edema or corneal staining ≥ grade 2
* Neovascularization or ghost vessels \> 1.0 mm in from the limbus
* Giant papillary conjunctivitis (GPC) of \> grade 2.
* Seborrheic eczema, seborrheic conjunctivitis or blepharitis
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CooperVision, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Center, University of California, Berkeley
Berkeley, California, United States
University of Manchester
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CV-10-50
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.